Gilead Sciences, Inc. (GILD)
After hours:
| Previous close | 63.27 |
| Open | 63.37 |
| Bid | 63.58 x 800 |
| Ask | 63.99 x 1800 |
| Day's range | 62.72 - 63.90 |
| 52-week range | 57.19 - 74.12 |
| Volume | |
| Avg. volume | 9,823,454 |
| Market cap | 80.075B |
| Beta (5Y monthly) | 0.39 |
| PE ratio (TTM) | 17.83 |
| EPS (TTM) | 3.58 |
| Earnings date | 27 Jul 2022 - 01 Aug 2022 |
| Forward dividend & yield | 2.92 (4.57%) |
| Ex-dividend date | 14 Jun 2022 |
| 1y target est | 69.35 |
- Zacks
Top Research Reports for JPMorgan, Gilead Sciences & CSX
Today's Research Daily features new research reports on 16 major stocks, including JPMorgan Chase & Co. (JPM), Gilead Sciences, Inc. (GILD) and CSX Corporation (CSX).
- Business Wire
Gilead Reaches Number One Spot as Top Overall Philanthropic Funder of HIV-Related Programs, According to Funders Concerned About AIDS Report
FOSTER CITY, Calif., May 19, 2022--Gilead Sciences, Inc. (Nasdaq: GILD) today was officially recognized as the number one philanthropic funder of HIV-related programs in a new tracking report released by Funders Concerned About AIDS (FCAA). The report, found at: https://www.fcaaids.org/inform/philanthropic-support-to-address-hiv-aids/, is released annually and is widely regarded as the most comprehensive study of its kind. It analyzes 2020 funding data (the most recent year available) revealing
- Zacks
Biotech Stock Roundup: BBIO Up on BMY Deal, GILD & CMRX Offer Updates
Regulatory updates and acquisition news from Bristol Myers' (BMY) and BridgeBio Pharma (BBIO) are a few key highlights from the biotech sector during the past week.
